Abstract
Almost 10 years after the discovery of Orphanin FQ / Nociceptin (OFQ/N) a large number of synthetic small molecule agonists and antagonists have been developed and tested in various physiological assays. Together with the academic work on the physiological functions of OFQ/N, we now have compelling evidence that this neuropeptide system might represent a valuable target for the development of drugs treating a variety of psychiatric disorders. Most prominently, the anti-stress and anxiolytic effects of OFQ/N agonists have been investigated although clinical trials have not yet been launched. Other possible applications of OFQ/N agonists and antagonists include treatment of depression, anorexia and rewarding aspects of drug addiction. This paper will summarize current developments and highlight the scientific achievements that have been made to elucidate the functions of OFQ/N with respect to psychiatric disorders.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
